Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

作者全名："Wang, Jun; Zhang, Bicheng; Peng, Ling; Liu, Xiufeng; Sun, Jianguo; Su, Chunxia; Wang, Huijuan; Zhao, Zheng; Si, Lu; Duan, Jianchun; Zhang, Hongmei; Li, Mengxia; Zhu, Bo; Zhang, Li; Li, Jin; Guo, Jun; Luo, Rongcheng; Qiu, Wensheng; Ye, Dingwei; Chu, Qian; Cui, Jiuwei; Dong, Xiaorong; Fan, Yun; Gao, Quanli; Guo, Ye; He, Zhiyong; Li, Wenfeng; Lin, Gen; Liu, Lian; Liu, Yutao; Qin, Haifeng; Ren, Shengxiang; Ren, Xiubao; Wang, Yongsheng; Xue, Junli; Yang, Yunpeng; Yang, Zhenzhou; Yue, Lu; Zhan, Xianbao; Zhang, Junping; Ma, Jun; Qin, Shukui; Wang, Baocheng"

作者地址："[Wang, Jun] Shandong First Med Univ, Dept Oncol, Affiliated Hosp 1, Jinan 250014, Peoples R China; [Wang, Jun] Shandong Prov Qianfoshan Hosp, Shandong Key Lab Rheumat Dis & Translat Med, Shandong Lung Canc Inst, Jinan 250014, Peoples R China; [Qin, Shukui] Eastern Theater Command Gen Hosp, Dept Hepatobiliary Oncol, Qinhuai Med Dist, Nanjing 210008, Peoples R China; [Wang, Baocheng] Peoples Liberat Army, Hosp 960, Dept Oncol, Jinan 250031, Peoples R China; [Zhang, Bicheng] Wuhan Univ, Ctr Canc, Renmin Hosp, Wuhan, Peoples R China; [Peng, Ling] Zhejiang Prov Peoples Hosp, Dept Pulm & Crit Care Med, Hangzhou, Peoples R China; [Liu, Xiufeng] Eastern Theater Command Gen Hosp, Dept Hepatobiliary Oncol, Qinhuai Med Dist, Nanjing, Peoples R China; [Sun, Jianguo; Zhu, Bo] Army Med Univ, Canc Inst, Xinqiao Hosp, Chongqing, Peoples R China; [Su, Chunxia; Ren, Shengxiang] Tongji Univ, Thorac Canc Inst, Sch Med, Dept Oncol,Shanghai Pulm Hosp, Shanghai, Peoples R China; [Wang, Huijuan] Henan Canc Hosp, Dept Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China; [Zhao, Zheng] Shannxi Canc Hosp, Dept Oncol, Xian, Peoples R China; [Si, Lu; Guo, Jun] Peking Univ, Canc Hosp & Inst, Dept Melanoma, Beijing, Peoples R China; [Duan, Jianchun; Liu, Yutao] Chinese Acad Med Sci & Peking Union Med Coll, Dept Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China; [Zhang, Hongmei] Air Force Med Univ, Dept Oncol, Xijing Hosp, Xian, Peoples R China; [Li, Mengxia] Army Med Univ, Ctr Canc, Daping Hosp, Chongqing, Peoples R China; [Li, Mengxia] Army Med Univ, Inst Surg Res, Chongqing, Peoples R China; [Zhang, Li; Yang, Yunpeng] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China; [Li, Jin; Guo, Ye; Xue, Junli] Tongji Univ, Dept Oncol, Shanghai East Hosp, Shanghai, Peoples R China; [Luo, Rongcheng] Guangzhou Univ Chinese Med, Ctr Canc, Jinshazhou Hosp, Guangzhou, Peoples R China; [Qiu, Wensheng] Qingdao Univ, Affiliated Hosp, Dept Oncol, Qingdao, Peoples R China; [Ye, Dingwei] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China; [Chu, Qian] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China; [Cui, Jiuwei] First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China; [Dong, Xiaorong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China; [Fan, Yun] Zhejiang Canc Hosp, Dept Thorac Oncol, Hangzhou, Peoples R China; [Gao, Quanli] Zhengzhou Univ, Dept Immunol, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Gao, Quanli] Henan Canc Hosp, Zhengzhou, Peoples R China; [He, Zhiyong; Lin, Gen] Fujian Canc Hosp, Dept Thorac Oncol, Fuzhou, Peoples R China; [He, Zhiyong; Lin, Gen] Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China; [Li, Wenfeng] Wenzhou Med Univ, Dept Oncol, Affiliated Hosp 1, Wenzhou, Peoples R China; [Liu, Lian] Shandong Univ, Cheeloo Coll Med, Dept Oncol, Qilu Hosp, Jinan, Peoples R China; [Qin, Haifeng] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China; [Ren, Xiubao] Tianjin Med Univ, Canc Inst & Hosp, Dept Immunol & Biotherapy, Tianjin, Peoples R China; [Wang, Yongsheng] Sichuan Univ, West China Hosp, GCP Ctr, Inst Clin Pharmacol, Chengdu, Peoples R China; [Yang, Zhenzhou] Chongqing Med Univ, Dept Oncol, Affiliated Hosp 2, Chongqing, Peoples R China; [Yue, Lu] Qingdao Municipal Hosp, Dept Oncol, Qingdao, Peoples R China; [Zhan, Xianbao] Navy Med Univ, Changhai Hosp, Dept Oncol, Shanghai, Peoples R China; [Zhang, Junping] Shanxi Bethune Hosp, Dept Canc Biotherapy, Taiyuan, Peoples R China; [Ma, Jun] Harbin Inst Hematol & Oncol, Harbin, Peoples R China"

通信作者："Wang, J (通讯作者)，Shandong First Med Univ, Dept Oncol, Affiliated Hosp 1, Jinan 250014, Peoples R China.; Wang, J (通讯作者)，Shandong Prov Qianfoshan Hosp, Shandong Key Lab Rheumat Dis & Translat Med, Shandong Lung Canc Inst, Jinan 250014, Peoples R China.; Qin, SK (通讯作者)，Eastern Theater Command Gen Hosp, Dept Hepatobiliary Oncol, Qinhuai Med Dist, Nanjing 210008, Peoples R China.; Wang, BC (通讯作者)，Peoples Liberat Army, Hosp 960, Dept Oncol, Jinan 250031, Peoples R China."

来源：THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001032049700001

JCR分区：Q2

影响因子：4.3

年份：2023

卷号：15

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：Chinese Society of Clinical Oncology; consensus; immune checkpoint inhibitor; recommendation; special population

摘要："Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, the clinical applications of ICIs in cancer patient populations with special issues, a term that refers to complex subgroups of patients with comorbidities, special clinical conditions, or concomitant medications who are routinely excluded from prospective clinical trials of ICIs or are underrepresented in these trials, represent a great real-world challenge. Although the Chinese Society of Clinical Oncology (CSCO) has provided recommendations for screening before the use of ICIs in special populations, the recommendations for full-course management remain insufficient. The CSCO Expert Committee on Immunotherapy organized leading medical oncology and multidisciplinary experts to develop a consensus that will serve as an important reference for clinicians to guide the proper application of ICIs in special patient populations. This article is a translation of a study first published in Chinese in The Chinese Clinical Oncology (ISSN 1009-0460, CN 32-1577/R) in May 2022 (27(5):442-454). The publisher of the original paper has provided written confirmation of permission to publish this translation in Therapeutic Advances in Medical Oncology."

基金机构：Chinese Society of Clinical Oncology (CSCO)

基金资助正文："The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Chinese Society of Clinical Oncology (CSCO)"